Abstracts tagged "Disease-Modifying Antirheumatic Drugs (Dmards)"

Abstract Number: 0533 • ACR Convergence 2024
Using Adalimumab Serum Concentration to Choose a Subsequent DMARD in Rheumatoid Arthritis Patients Failing Adalimumab Treatment (ADDORA-switch): Results of a Blinded Randomized Test Treatment Trial
Maike Wientjes¹, Sadaf Atiqi², Gertjan Wolbink³, Michael Nurmohamed⁴, Maarten Boers⁵, Femke Hooijberg², Theo Rispens⁶, Annick De Vries⁶, Floris Loeff⁶, Ronald Van Vollenhoven⁷, Sofia Ramiro⁸, Noortje van Herwaarden⁹, Bart van den Bemt¹⁰ and Alfons den Broeder¹, ¹Sint Maartenskliniek, Ubbergen, Netherlands, ²Reade, Amsterdam, Netherlands, ³Reade and Sanquin Diagnostic Services, Amsterdam, Netherlands, ⁴Reade and Amsterdam UMC, Kortenhoef, Netherlands, ⁵Amsterdam UMC, Vrije Universiteit, Amersfoort, Netherlands, ⁶Sanquin Diagnostic Services, Amsterdam, Netherlands, ⁷Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁸Leiden University Medical Center, Bunde, Netherlands, ⁹Sint Maartenskliniek, Nijmegen, Netherlands, ¹⁰Sint Maartenskliniek / Radboudumc, Ubbergen, Netherlands
Background/Purpose: Adalimumab is an effective and safe treatment for RA, however a substantial proportion of RA patients discontinue its use due to inefficacy. Upon failure,…
Abstract Number: 1018 • ACR Convergence 2024
Analysis of Medication Usage and Monthly Costs in Hospitalized Patients with Rheumatic Diseases: A Retrospective Observational Study
Daniela Alejandra Salcedo-Soto¹, Ana Cecilia Bardan-Inchaustegui², Pablo Gamez-Siller³, Deynna Montserrat Lara Mendez⁴, Diana Elsa Flores-Alvarado⁵, Jorge Esquivel-Valerio⁶, Jesus Cardenas-de la Garza² and Dionicio Galarza-Delgado⁷, ¹Hospital Universitario Dr Jose Eleuterio Gonzalez, Monterrey, Mexico, ²Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ³Facultad de Medicina UANL, Monterrey, Nuevo León, Mexico, ⁴Hospital Universitario Dr José Eleuterio González, Monterrey, Nuevo León, Mexico, ⁵Hospital Universitario Jose Eleuterio Gonzalez, Monterrey, Nuevo León, Mexico, ⁶Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, MONTERREY, Mexico, ⁷UANL Hospital Universitario, Monterrey, Nuevo León, Mexico
Background/Purpose: Costs associated with rheumatic diseases significantly affect a considerable portion of patients’ income. The monthly income of northeastern Mexican families has been reported to…
Abstract Number: 1384 • ACR Convergence 2024
Disease-modifying Antirheumatic Drugs and Risk of Incident Interstitial Lung Disease Among Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Qianru Zhang¹, Gregory McDermott², Sung Hae Chang³, Pierre-Antoine Juge⁴, Kathleen Vanni⁵, Grace Qian⁶, Katarina Bade⁵, Kevin Mueller⁵, Emily Kowalski⁵, Alene Saavedra⁵ and Jeffrey Sparks⁷, ¹Harard Medical School, Cambridge, ²Brigham and Women's Hospital, Brookline, MA, ³Soonchunhyang University College of Medicine, Bongmyeong-dong, Dongnam-gu, Cheonan-si, South Korea, ⁴Service de Rhumatologie, Hôpital Bichat - Claude-Bernard, AP-HP, Paris, Île-de-France, France, PARIS, Germany, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Brigham and Women’s Hospital, Boston, MA, ⁷Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA
Background/Purpose: Interstitial lung disease (ILD) is a serious extra-articular manifestation of RA, affecting 7-12% of patients and associated with three-fold increased mortality compared to RA…
Abstract Number: 1695 • ACR Convergence 2024
Efficacy of Upadacitinib in Patients with Giant Cell Arteritis: Subgroup Analysis of the SELECT-GCA Phase 3 Trial
Peter Merkel¹, Arathi Setty², Ricardo Blanco-Alonso³, Ravi Suppiah⁴, Thomas Daikeler⁵, Valerie Devauchelle⁶, Elisabeth Brouwer⁷, Hiromichi Tamaki⁸, Liu Meng², Yang Yang², Avani Joshi², Charles Phillips², Peter K. Wung² and Cristina Ponte⁹, ¹Division of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, ²AbbVie, North Chicago, IL, ³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain, ⁴Health New Zealand, Te Toka Tumai Auckland, Auckland, New Zealand, ⁵university hospital, Basel, Switzerland, ⁶UBO, Brest, France, ⁷University Medical Center Groningen, Groningen, Netherlands, ⁸St. Luke's International Hospital, Tokyo, Japan, ⁹Unidade Local de Saúde Santa Maria, Serviço de Reumatologia e Doenças Ósseas Metabólicas, Lisboa, Portugal., Lisbon, Portugal
Background/Purpose: Giant cell arteritis (GCA) is a chronic systemic vasculitis with limited targeted therapeutic options. The recent SELECT-GCA phase 3 trial demonstrated a favorable benefit-risk…
Abstract Number: 2077 • ACR Convergence 2024
Comparison of Janus Kinase Inhibitors to Block the Type I and II Interferon Pathways in Human Myoblasts
Travis Kinder and James Inglese, National Institutes of Health, Rockville, MD
Background/Purpose: The family of Janus kinases (JAK1, JAK2, JAK3, TYK2) mediate signal transduction from cytokine receptors through phosphorylation and activation of intracellular signaling pathways and…
Abstract Number: 2352 • ACR Convergence 2024
Bimekizumab Treatment Was Efficacious to 2 Years Regardless of Duration of axSpA Symptoms: Results from Two Phase 3 Studies
Sofia Ramiro¹, Fabian Proft², Raj Sengupta³, Astrid van Tubergen⁴, Anna Molto⁵, Lianne S Gensler⁶, Mitsumasa Kishimoto⁷, Vanessa Taieb⁸, Diana Voiniciuc⁹, Ute Massow¹⁰ and Victoria Navarro Compán¹¹, ¹Leiden University Medical Center, Bunde, Netherlands, ²Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ³Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁴Department of Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁵Groupe Hospitalier Cochin, AP-HP, Paris, France, ⁶Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁷Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, ⁸UCB Pharma, Colombes, France, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰UCB Pharma, Monheim am Rhein, Germany, ¹¹La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain
Background/Purpose: Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A, showed efficacy to Week (Wk) 52 in patients (pts) with…
Abstract Number: 0059 • ACR Convergence 2024
Fragment Crystallizable (Fc)-Free Certolizumab Pegol Is Not Bound by Rheumatoid Factors, While Fc Containing Biological DMARDsAre, Driving ImmuneComplex Formation and Cellular Clearance
Susanna R. Bidgood¹, Sophie Hopkin¹, Kathryn R. Malpas¹, David M. Kallenberg¹, Jacqueline O’Neill¹, Geofrey Odede¹, Bernard Lauwerys², Baran Ufuktepe³ and David Humphreys¹, ¹UCB Biopharma UK, Slough, United Kingdom, ²UCB Pharma, Brussels, Belgium, ³UCB Pharma, Istanbul, Turkey
Background/Purpose: RFs are polyclonal autoantibodies which bind the Fc domain of IgGs. Patients with RA and high RF levels have poorer prognosis, more severe progressive…
Abstract Number: 0404 • ACR Convergence 2024
Methotrexate Adherence in JIA: Use of Electronic Health Record-Linked Pharmacy DispensingData
Dori Abel¹, David Anderson¹, Michael Kallan², Levon Utidjian³, Jon Burnham⁴, Joyce Chang⁵, Chen Kenyon³ and Sabrina Gmuca¹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, ³Children's Hospital of Philadelphia, Philadelphia, ⁴Children's Hospital of Philadelphia, Bryn Mawr, PA, ⁵Boston Children's Hospital, Boston, MA
Background/Purpose: The extent to which adherence to prescribed treatment regimens contributes to differential disease outcomes in JIA – and demographic disparities in these outcomes –…
Abstract Number: 0582 • ACR Convergence 2024
Achievement of Minimal and Very Low Disease Activity Among Patients with Psoriatic Arthritis Initiating Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in the CorEvitas PsA/SpA Registry
Alexis Ogdie¹, Chao Song², Nicole Middaugh³, Maya Marchese³, Melissa Eliot³, Robert Low² and Philip Mease⁴, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²UCB Pharma, Smyrna, GA, ³CorEvitas, LLC, Waltham, MA, ⁴Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA
Background/Purpose: Minimal disease activity (MDA) is associated with clinically meaningful improvements in disease activity and patient (pt)-reported outcomes among pts with PsA.1 However, it is…
Abstract Number: 1037 • ACR Convergence 2024
Recommendations for the Perioperative Use of DMARDs in Rheumatic Diseases: A Scoping Review
Alice Terrett¹, Athena Chin², Mihye Kwon³, Samuel Whittle⁴ and Catherine Hill⁵, ¹The Queen Elizabeth Hospital, Adelaide, Australia, ²Royal Adelaide Hospital, Tranmere, South Australia, Australia, ³Konyang University, College of Medicine, Daejeon, Republic of Korea, ⁴The Queen Elizabeth Hospital, Springfield, South Australia, Australia, ⁵The Queen Elizabeth Hospital, Woodville, South Australia, Australia
Background/Purpose: The use of disease-modifying anti-rheumatic drugs (DMARDs) in the treatment of autoimmune rheumatic diseases, including rheumatoid arthritis (RA), has significantly improved disease and functional…
Abstract Number: 1392 • ACR Convergence 2024
Safety and Efficacy of Upadacitinib (UPA) in Japanese Patients with Rheumatoid Arthritis (RA) and Inadequate Response to Conventional Synthetic DMARDs: Results Through 5 Years from the SELECT-SUNRISE Study
Hideto Kameda¹, Tsutomu Takeuchi², Kunihiro Yamaoka³, Motohiro Oribe⁴, Mitsuhiro Kawano⁵, Masayuki Yokoyama⁶, Yuko Konishi⁶, Sumi Chonan⁶, Sara Penn⁷, Heidi S Camp⁷ and Yoshiya Tanaka⁸, ¹Toho University, Tokyo, Japan, ²Department of Internal Medicine, Keio University, Tokyo, Tokyo, Japan, ³Kitasato University School of Medicine, Kanagawa, Japan, ⁴Oribe Clinic of Rheumatism and Medicine, Oita, Japan, ⁵Kanazawa Medical University, Ishikawa, Japan, ⁶AbbVie GK, Tokyo, Japan, ⁷AbbVie, North Chicago, IL, ⁸Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan
Background/Purpose: To evaluate the efficacy and safety of UPA in Japanese RA patients (pts) up to 5 yrs in a long term extension (LTE) of…
Abstract Number: 1697 • ACR Convergence 2024
Results of a One Year Randomized Double-Blind Placebo-Controlled Trial with Methotrexate 25mg Per Week for Recently Diagnosed PolyMyalgia Rheumatica
Thomas Bolhuis¹, Noortje Kooijman¹, Diane Marsman¹, Gijs Snijders², Alfons den Broeder³, Nathan den Broeder⁴ and Aatke Van der maas⁵, ¹Department of Rheumatology, Sint Maartenskliniek, Ubbergen, The Netherlands, Ubbergen, Netherlands, ²Department of Rheumatology, Gelre Ziekenhuizen, Apeldoorn, The Netherlands, Gelre, Netherlands, ³Sint Maartenskliniek, Ubbergen, Netherlands, ⁴Sint Maartenskliniek, Ubbergen, Gelderland, Netherlands, ⁵St Maartenskliniek, Ubbergen, Netherlands
Background/Purpose: The most effective treatment for Polymyalgia rheumatica (PMR) are glucocorticoids (GC), but these are associated with toxicity. Three randomized controlled trials (RCTs) suggest methotrexate…
Abstract Number: 2121 • ACR Convergence 2024
Increased Fracture Rates in Patients Continuing Methotrexate After Methotrexate-associated Lower Limb Insufficiency Fractures: A Retrospective Follow-up Study
Roba Ghossan¹, OLIVIER FOGEL², Christian Roux¹ and Karine Briot¹, ¹COCHIN HOSPITAL, PARIS, France, ²AP-HP, Paris, France
Background/Purpose: Spontaneous lower limb insufficiency fractures (LLIF) described under prolonged exposure to low-dose methotrexate are often bilateral, multiple, and recurrent. They share a common pathognomonic…
Abstract Number: 2431 • ACR Convergence 2024
DORIS Remission in Patients with SLE Treated with Anifrolumab: Post Hoc Analysis from TULIP-1 and TULIP-2 Trials in Patents with No Reported History of Prior Immunosuppressant Use
doria Andrea¹, Ronald Van Vollenhoven², Eric Morand³, Catharina Lindholm⁴, Jonatan Hedberg⁴, Miina Waratani⁵ and Danuta Kielar⁶, ¹University of Padova, Padova, Italy, ²Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands, ³School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia, ⁴BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden, ⁵Biopharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ⁶Biopharmaceuticals Medicine, AstraZeneca, Cambridge, United Kingdom
Background/Purpose: 2023 EULAR recommendations for the management of SLE open up the option for early treatment initiation with biologics without the requirement to fail immunosuppressants/DMARDs…
Abstract Number: 0076 • ACR Convergence 2024
Early (3-Month) and Maintained (12-Month) Comparative Effectiveness of 5 Different Classes of Advanced Therapies in a Large Multinational Cohort of Real-World PsA Patients
William Tillett¹, Rieke Alten², Ennio Lubrano³, Khai Jing Ng⁴, Marcus Ngantcha⁵, Inmaculada de la Torre⁴, Dominika Kennedy⁶, Nicola Gullick⁷ and Dennis McGonagle⁸, ¹Royal National Hospital of Rheumatic Diseases; Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom, ²Department of Internal Medicine and Rheumatology, Schlosspark Klinik, University Medicine Berlin, Berlin, Germany, ³Vincenzo Tiberio Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy, ⁴Eli Lilly and Company, Madrid, Spain, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Eli Lilly and Company, Indianapolis, ⁷Rheumatology Department, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, Coventry, United Kingdom, ⁸National Institute for Health Research (NIHR) Leeds Biomedical Research Centre (BRC), Leeds Teaching Hospitals, Leeds, UK, Leeds, England, United Kingdom
Background/Purpose: The primary objective was to report persistence at 24 months among patients who initiated a new b/tsDMARD. Secondary endpoints included descriptive and comparative effectiveness…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].